癌症诊断联合研究和许可协议（2018-2024）

Cancer Diagnostic Collaboration and Licensing Deals 2018-2024

出版日期: 2024年11月01日 | 出版商:

Current Partnering | 英文 450+ Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告审查了癌症诊断合作和许可协议，详细瞭解和分析了公司如何以及为何签订癌症诊断协议。

简介
过去几年的癌症诊断合约
最活跃的癌症诊断合约公司
癌症诊断合约：依合约类型
癌症诊断合约：依治疗领域
癌症诊断合约：依行业分类
癌症诊断合约条款与条件
- 癌症诊断合约的总金额
- 癌症诊断合约预付款
- 癌症诊断合约的里程碑付款
- 癌症诊断特许权使用费

第3章主要癌症诊断合约

简介
以价值排名最高的癌症诊断合约

第4章最活跃的癌症诊断合约公司

简介
最活跃的癌症诊断合约公司
最活跃的癌症诊断合约公司简介

第5章癌症诊断合约目录

简介
癌症诊断合约目录

第 6 章癌症诊断合约：依技术类型

合约目录
合约目录 - 癌症诊断合约：依公司分类（A-Z）
合约目录 - 癌症诊断合约：依合约类型
合约目录 - 癌症诊断合约：依治疗领域
合约类型的定义
关于生物製药研究股份有限公司
当前合作伙伴
当前协议
Current Partnering 近期报告的标题

简介目录

Product Code: CP22013

Cancer Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer diagnostic deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of cancer diagnostic deals from 2018 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter cancer diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 702 cancer diagnostic deals announced since 2018 including financial terms where available including links to online deal records of actual cancer diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cancer diagnostic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cancer diagnostic dealmaking since 2018.

Chapter 3 provides an overview of the leading cancer diagnostic deals since 2018. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer diagnostic dealmaking with a brief summary followed by a comprehensive listing of cancer diagnostic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cancer diagnostic deals signed and announced since Jan 2018, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of cancer diagnostic partnering deals signed and announced since Jan 2018. The chapter is organized by specific cancer diagnostic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cancer diagnostic deal making since 2018.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cancer Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2018
Browse cancer diagnostic collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Cancer Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cancer diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.

Cancer Diagnostic Collaboration and Licensing Deals includes:

Trends in cancer diagnostic dealmaking in the biopharma industry
Directory of cancer diagnostic deal records covering pharmaceutical and biotechnology
The leading cancer diagnostic deals by value
Most active cancer diagnostic licensing dealmakers
Cancer Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer diagnostic dealmaking

2.1. Introduction
2.2. Cancer diagnostic deals over the years
2.3. Most active cancer diagnostic dealmakers
2.4. Cancer diagnostic deals by deal type
2.5. Cancer diagnostic deals by therapy area
2.6. Cancer diagnostic deals by industry sector
2.7. Deal terms for cancer diagnostic deals
- 2.7.1 Cancer diagnostic deals headline values
- 2.7.2 Cancer diagnostic deal upfront payments
- 2.7.3 Cancer diagnostic deal milestone payments
- 2.7.4 Cancer diagnostic royalty rates